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1. Introduction 
For decades, control of cellular behavior was thought to be the exclusive purview of protein-
based regulators. However, the recent discovery of small RNAs (sRNAs) as a universal class 
of powerful RNA-based regulatory biomolecules has the potential to revolutionize our 
understanding of gene regulation in practically all biological functions, as sRNAs have been 
found in diverse organisms from bacteria to plants to man. A class of sRNAs in eukaryotes, 
termed microRNAs (miRNAs), has been found to modulate a wide variety of cellular 
functions, including cell growth, cell differentiation, and apoptosis. miRNAs function as 
regulators by base-pairing with trans-encoded mRNAs to prevent translation of mRNA into 
protein at the post-transcriptional level. By modulating the expression levels of target genes, 
miRNAs enable rapid adaptation of cellular physiology in response to specific 
environmental changes. It is estimated that at least ~30% of the human genome is regulated 
by miRNAs. (Lewis, et al., 2005) In this review, we will discuss recent discoveries that 
implicate miRNA function in host immunity, including specific miRNA expression in 
immune cells and their regulation of immune cell development, miRNA regulation of innate 
and acquired immune response, and viral-encoded miRNAs. These recent advances have 
strong potential to translate fundamental research in miRNA function into clinical 
applications. We will also describe the challenges in bringing another RNA interference 
(RNAi) methodology, small interfering RNA (siRNA), to clinical trials. This analysis will 
serve as a practical roadmap for development of novel miRNA-based therapies to combat 
infectious disease by reducing the host inflammatory response and the downstream effects 
of pathogen infection. 
2. miRNA biogenesis and mechanism of action  
Most miRNAs are transcribed by RNA polymerase II as either polycistronic or 
monocistronic transcription units called primary miRNAs (pri-miRNAs), in which one or 
more hairpin structures with ~33bp stem regions and terminal loops are embedded. (Fig. 1) 
(Lee, et al., 2004) These pri-miRNAs are capped and polyadenylated and can be as long as 
several kilobases. (Cai, et al., 2004) Hairpin structures embedded within pri-miRNA 
transcripts are recognized and excised by the microprocessor complex in the nucleus, which 
consists of the RNase III-like enzyme Drosha and double-stranded RNA (dsRNA) binding 
protein DGCR8 (DiGeorge syndrome critical region gene 8). (Landthaler, et al., 2004, Lee, et  
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Fig. 1. miRNA biogenesis and mechanism of action. miRNAs are initially transcribed as 
either polycistronic or monocistronic long primary miRNA transcripts (pri-miRNAs), and 
then undergo a series of maturation steps including: (1) cleavage by the enzyme Drosha into 
the intermediate precursor miRNAs (pre-miRNAs), (2) transport from the nucleus to the 
cytoplasm via Exportin 5, and (3) final processing by the enzyme Dicer into the mature 
miRNA duplexes for loading into the RNA-induced silencing complex (RISC). Plant 
miRNAs pair extensively with their target mRNAs, resulting in direct cleavage of the 
mRNAs. Mammalian miRNAs exhibit partial complementarity with the 3’ untranslated 
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al., 2003) The released hairpin structure is typically ~65-70 nt and is referred to as a 
precursor miRNA (pre-miRNA). (Lee, et al., 2002) Pre-miRNAs are then exported into the 
cytoplasm by Exportin-5 (EXP5) in a Ran-GTP dependent manner. (Yi, et al., 2003) In the 
cytoplasm, the end opposite to Drosha cleavage in the mature miRNA is cleaved by another 
RNase III enzyme, Dicer, yielding a 22-25nt duplex. (Hutvagner, et al., 2001, Ketting, et al., 
2001) Once the mature miRNA duplex is created, one strand of the duplex is loaded into a 
multi-protein complex, RNA-induced silencing complex (RISC), to direct subsequent 
miRNA:mRNA target interaction and gene silencing. (Bartel, 2004, Filipowicz, et al., 2008) 
This strand is called the guide strand (miRNA), while the other strand is termed the 
passenger strand (miRNA*), which usually undergoes degradation. There are cases where 
both strands can mediate subsequent gene silencing. The determination of guide/passenger 
strand is believed to depend on the thermodynamic stability of the base pairing at the ends 
of the duplex. The strand whose 5’ end displays less stability will become the guide strand. 
(Khvorova, et al., 2003) The catalytic component of RISC is the Argonaute (AGO) protein, 
which mediates binding and silencing of the target mRNAs. (Pillai, et al., 2004) 
In general, miRNAs down-regulate translation by binding to the miRNA response elements 
(MREs) in the 3’UTR (3’ untranslated region) of their mRNA targets to cause inhibition of 
mRNA translation, and in some cases, mRNA destabilization. (Filipowicz, et al., 2008) 
Complementarity between miRNAs and MREs have been shown to be near perfect in 
plants, but only partial in animals. Multiple mechanisms of action have been proposed. 
AGO proteins in RISC may inhibit translation initiation by competing with eIF4E for mRNA 
m7G cap-recognition. (Kiriakidou, et al., 2007, Mathonnet, et al., 2007) Alternatively, RISC 
may inhibit translation initiation by preventing the assembly of 80S ribosomes via 
recruitment of eIF6. (Chendrimada, et al., 2007) There is also evidence that RISC can repress 
translation post-initiation by causing ribosome drop-off or nascent polypeptide degradation 
during the elongation step. (Petersen, et al., 2006) Finally, miRNAs can accelerate mRNA 
destabilization. miRNA-associated targets were found to be enriched in P-bodies, 
compartmentalized cytoplasmic foci where mRNA decay occurs (Sheth and Parker, 2003), 
and to be associated with deadenylase, decapping enzymes and exonucleases. (Behm-
Ansmant, et al., 2006, Liu, et al., 2005) 
miRNA target identification in animals is relatively difficult because of imperfect 
miRNA:MRE complementarity. One important finding is the so-called “seed rule”, in which 
extensive Watson-Crick base paring between the “seed” region (2-7 nt from the 5’ end) of 
the miRNA and its target, remarkably reduces the number of false positive predictions. 
(Lewis, et al., 2003, Lim, et al., 2005) The seed rule has been widely applied as the 
fundamental criteria by most current prediction algorithms to screen for potential miRNA 
target genes. Nevertheless, considerable evidence exists to argue that the seed pairing is 
either not required or not sufficient for predicting miRNA:mRNA interactions. (Didiano and 
Hobert, 2006) Other features within 3’UTRs, in addition to seed pairing, have been 
demonstrated to be important determinants, including overall thermodynamic stability of 
miRNA:mRNA duplex, total number of MREs within the 3’UTR, accessibility of the MRE, 
position of the MRE related to the stop codon, and local AU rich elements. (Hon and Zhang, 
2007, Kertesz, et al., 2007, Li, et al., 2008) Thus, current computational target prediction is far 
from established, and predicted target candidates need to be experimental verified. 
Both biogenesis and function of miRNAs are subject to tight regulation. Almost every aspect 
of miRNA biogenesis, from transcription and processing to subcellular localization and 
stability, can be regulated in a sequence-specific and cell-specific manner. Such regulation is 
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believed to be important for many developmental and physiological processes. For example, 
the transcription factors Myogenin and MyoD1 induce expression of miR-1 and miR-133 
specifically during myogenesis. (Rao, et al., 2006) During stem cell differentiation, the levels 
of pri-let-7 remain constant, while the levels of mature let-7 duplex increase. (Piskounova, et 
al., 2008) Interestingly, post-transcriptional suppression of let-7 in undifferentiated cells is 
mediated by its target Lin-28. Lin-28 not only blocks microprocessor cleavage in the nucleus 
by directly binding to the loop region of pri-let-7, (Piskounova, et al., 2008) but also prevents 
Dicer cleavage in the cytoplasm by promoting polyuridylation and degradation of pre-let-7. 
(Heo, et al., 2009) The nuclear export of miRNA is usually the rate-limiting step of miRNA 
biosynthesis. (Grimm, et al., 2006) Some pre-miRNAs such as human pre-miR-31, pre-miR-
128, and pre-miR-105 are retained in the nucleus instead of being processed into mature 
miRNAs in certain cell types. (Lee, et al., 2008) Finally, although the degradation of miRNAs 
is not well-understood, the enrichment of guide strands but not passenger strands in the 
cells clearly indicates the existence of an as-yet unknown mechanism that quickly and 
selectively turns over these small RNAs. A family of exoribonucleases that degrades 
miRNAs have been identified in A. thaliana. (Ramachandran and Chen, 2008) Furthermore, 
under certain conditions, miRNA-mediated silencing can be reversed or blocked. (Kedde, et 
al., 2007, Schratt, et al., 2006) For example, mir-122-mediated repression of CAT1 (cationic 
amino acid transporter 1) can be alleviated in human cells lines as a response to starvation 
or other types of cell stress. (Bhattacharyya, et al., 2006) 
3. miRNAs and the host immune system 
Mammalian systems have developed a complex system of checks and balances to regulate 
gene expression in order to respond to pathogen infection. In the last several years, miRNAs 
are increasingly becoming implicated in the regulation of both immune cell development 
and function. Proper functioning of the immune system requires elaborate control of both 
innate and adaptive immune response in order to defend against various pathogens while 
maintaining self tolerance. miRNAs are required for normal immune system function by 
helping to maintain this balance. miR-146a is upregulated in human monocytes upon 
exposure to lipopolysaccharide (LPS), a cell wall component of Gram negative bacteria and 
established activator of innate immunity. Its upregulation is dependent on NF-B, a key 
transcription factor that regulates practically all aspects of the innate immune response, such 
as synthesis of pro-inflammatory cytokines, including TNF and IL-1, and regulation of 
immune cell migration. Interestingly, TRAF6 (TNF receptor-associated factor 6) and IRAK1 
(IL-1 receptor-associated kinase 1), two components of the Toll-like receptor 4 (TLR4) 
signaling pathway that act upstream of NF-B, were found to be targets of miR-146a. These 
findings suggest that miRNAs function in the negative feedback regulation of TLR signaling 
in order to ensure appropriate strength and duration of the innate immune response. 
(Taganov, et al., 2006) Another inflammatory mediator, miR-155, is induced by LPS (Ceppi, 
et al., 2009, O'Connell, et al., 2007, Tili, et al., 2007) and nucleic acids, including poly(I:C) 
(polyriboinosinic:polyribocytidylic acid) and hypomethylated DNA (O'Connell, et al., 2007), 
implicating function in both bacterial and viral infection. miR-155 is proposed to fine tune 
inflammatory cytokine production through negative feedback loops by targeting TAB2 
(Ceppi, et al., 2009), FADD (fas-associated death domain protein), IKK (IB kinase ), and 
Ripk1 (receptor-interacting serine-threonine kinase 1). (Tili, et al., 2007)  
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In addition to innate immunity, the adaptive immune response is also subject to regulation 
by miRNAs, in particular miR-155. miR-155-deficient dendritic cells exhibited impaired 
ability in antigen presentation and T cell activation, suggesting its involvement in bridging 
innate and adaptive immunity. (Rodriguez, et al., 2007) miR-155 restricts Th2 but not Th1 
lineage commitment after CD4+ T cell activation (Rodriguez, et al., 2007, Thai, et al., 2007), 
and is also required for the differentiation and proliferation of regulatory T helper cells, 
which function to self-limit the immune response. (Kohlhaas, et al., 2009, Lu, et al., 2009) 
Furthermore, miR-155 was induced in B lymphocytes upon activation and regulates the 
germinal center response and generation of immunoglobulin class-switched plasma cells. 
(Teng, et al., 2008, Thai, et al., 2007, Vigorito, et al., 2007) Naïve B lymphocytes express only 
immunoglobulin M (IgM) isotype antibodies on the cell surface as a result of V(D)J DNA 
recombination. Upon activation, B lymphocytes undergo somatic hypermutation (SHM), 
gene conversion (GCV), affinity maturation, and class-switched recombination (CSR) to 
produce a vast antibody repertoire with increased diversity, higher antigen-binding affinity, 
and different isotypes. miR-155 has been shown to regulate expression of activation-induced 
cytidine deaminase (AID), which catalyzes the SHM, GCV and CSR processes by 
deaminating cytosine to introduce U:G mismatches in Ig genes. (Teng, et al., 2008) 
Disruption of miR-155-AID interaction in vivo results in quantitative and temporal 
alteration of AID expression and defective antibody maturation. Another target of miR-155, 
the transcription factor PU.1, has been reported to be involved in the reduction of IgG1-
switched plasma cells in a miR-155 deficient mouse model. (Vigorito, et al., 2007) 
Several miRNAs have also been implicated in different immune development processes. 
miR-223 is activated by the myeloid transcription factors PU.1 and C/EBP 
(CCAAT/enhancer-binding protein) and has been shown to control granulocyte 
development. (Fazi, et al., 2005, Johnnidis, et al., 2008) miR-150 is an important regulator of 
B cell differentiation through targeting of the transcription factor c-Myb. (Xiao, et al., 2007, 
Zhou, et al., 2007) Finally, miR-181a modulates T cell receptor sensitivity and signaling 
strength during positive and negative selection, most likely through downregulation of 
phosphatases. (Li, et al., 2007)  
4. miRNAs and viruses 
Interestingly, miRNAs have been identified in various members of the herpesvirus family, 
such as Epstein-Barr virus (EBV), herpes simplex virus 1 (HSV-1), Kaposi’s sarcoma-
associated herpesvirus (KSHV), and human cytomegalovirus (HCMV), during both the 
latent and the productive stage of the viral life cycle. These viral miRNAs share the same 
biogenesis and execution pathways as their cellular counterparts, and downregulate either 
viral or host mRNAs in order to evade the host immune system or to control the transition 
from latent to the productive replication stage. (Cullen, 2009) For example, the degradation 
of EBV DNA polymerase mRNA by miR-BART2 (Barth, et al., 2008), the suppression of 
HSV-1 immediate early proteins ICP0 and ICP4 by miR-H2-3p and miR-H6 (Umbach, et al., 
2008), and the downregulaton of HCMV viral immediate-early protein IE1 by miR-UL112-1 
(Murphy, et al., 2008), help to establish and maintain viral latency. KSHV miRNA miR-K12-
6-3p contributes to the formation of Kaposi’s sarcoma tumors in vivo by downregulation of 
host gene THBS1 (thrombospondin 1). (Samols, et al., 2007) Downregulation of host MICB 
mRNA (major histocompatibility complex class I polypeptide-related sequence B), a ligand 
for natural killer cells, by HCMV miRNA miR-UL112-1 protects infected cells from natural 
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killer cells. (Stern-Ginossar, et al., 2007) Another host antiviral gene CXCL11 (CXC-
chemokine ligand 11), a target of EBV miRNA miR-BHRF1-3, is downregulated to protect 
infected B cells from being targeted by cytotoxic T cells. (Xia, et al., 2008)  
5. Targeting miRNA expression to modulate gene expression 
Medical countermeasures that exploit miRNA function have focused on therapies for 
cancer. Different approaches have been developed to manipulate expression levels of 
miRNAs and determine downstream effects on disease. (Fig. 2) A number of studies have 
demonstrated that specific miRNAs exhibit altered expression levels in tumors, and that 
“normalization” of miRNA expression in cancer cells may have a therapeutic effect. To up-
regulate miRNA expression, either miRNA mimics or miRNA expression vectors can be 
overexpressed in target cells and tissues. Mirna Therapeutics has reported the systemic 
delivery of mimics for miR-34 and let-7 via a neutral lipid emulsion, as a strategy for 
miRNA replacement therapy to inhibit tumor growth and metastasis in a mouse model. 
(Trang, et al., 2011, Wiggins, et al., 2010) Both miR-34 and let-7 are natural tumor 
suppressors that exhibit reduced expression in different cancers. Introduction of the mimics 
in mice led to ~60% reduction in tumor area compared to control mice. These results offer a 
novel therapeutic strategy for cancer by restoring miR-34 and let-7 expression to wild-type 
levels to reduce tumor growth. Given that miR-34 and let-7 levels are reduced in a number 
of different cancers, it may be the case that synthetic miRNA mimics can have broad 
applicability as anti-cancer agents.  
Inhibitory agents that down-regulate miRNA expression, termed antagomirs, have been 
developed to pair with mature miRNAs through sequence complementarity and block 
miRNA-mediated gene regulation. (Hutvagner, et al., 2004, Krutzfeldt, et al., 2005) 
Development of antagomirs that contain locked nucleic acids (LNAs), a backbone 
modification in which the ribose moiety has been locked by an oxymethylene bridge 
connecting the C(2’) and C(4’) atoms of the ribose, have yielded unusually stable 
oligonucleotides with high duplex melting temperatures for more robust therapeutic 
studies. Their relatively small size, high affinity, and potential for systemic delivery without 
complicated delivery vehicles has established LNA oligos as a favorite platform for design 
of RNA-based drug candidates. Antagomirs against miR-16, miR-122, miR-192, and miR-
194, conjugated to cholesterol, have been intravenously administered in mice, and 
corresponding miRNA levels exhibited marked reduction in multiple organs and tissues. A 
systemically administered unconjugated LNA-anti-miR-122 oligonucleotide led to specific, 
dose-dependent silencing of miR-122 in non-human primates. (Elmen, et al., 2008) This 
particular anti-miR was composed of 15 nucleotides, which covered the seed sequence in the 
3’ UTR of miR-122 and adjacent nucleotides. In a recent study, 7-mer and 8-mer anti-miRs 
that only targeted the seed sequence exhibited potent inhibition of miR-21, which exhibits 
elevated levels in a variety of cancers. (Obad, et al., 2011) These short anti-miRs form strong 
hybrids with their target miRNAs and sterically block miRNA function. Injection of anti-
miR-21 into mice yielded sequestration of the hybrid complex in the main organs and 
resultant upregulation of a miR-21 gene target. Their enhanced stability and relatively small 
size positions these seed-directed anti-miRs as potentially strong drug candidates to target 
specific miRNAs or miRNA families that function in disease onset. 
Viral miRNAs are potential anti-viral candidates for therapeutic development and can serve 
as diagnostic markers for viral infection or specific stages of disease. The host miR-122, 
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which has two recognition sites in the 5’ UTR of the hepatitis C virus (HCV) genome, is 
required for virus replication. (Jopling, et al., 2005) Use of specific antagonists that target miR-
122 resulted in a reduction in HCV in the liver of a primate model, demonstrating the 
therapeutic utility of this strategy.(Lanford, et al., 2010) The anti-miR-122 treatment provided 
continued efficacy in the animals up to several months after the treatment period with no 
adverse effects or evidence of viral rebound. Based on these studies, Santaris Pharma A/S has 
initiated the first miRNA-targeted Phase 2a clinical trial, based on the miR-122-inhibitory drug, 
Miravirsen, to assess safety and tolerability in up to 55 treatment-naïve patients infected with 
HCV. Designed using LNA technology, Miravirsen sequesters miR-122 from HCV, thus 
inhibiting replication of the virus. Secondary validation studies, including drug 
pharmacokinetics and effect on viral load, will be assessed. miRNA technology has also been 
applied to vaccine development for influenza virus. A miRNA-responsive element (MRE) was 
introduced into the viral nucleoprotein gene to control the level of viral attenuation via miR-
124, which targets the MRE sequence. The resulting viruses produced a species-specific 
vaccine that generated high levels of neutralizing antibodies in the host. (Perez, et al., 2009)  
 
 
Fig. 2. (A) In general, miRNAs bind to the 3’ UTR of target genes to downregulate gene 
expression. (B) miRNA mimics provide increased numbers of miRNAs by overexpression or 
synthetic copies to enhance miRNA function. (C) Inhibition of miRNA function can be 
achieved by usage of (1) antagomirs, stable complementary oligonucletides, that hybridize 
to target miRNAs, or with (2) miRNA sponges, which provide alternative binding platforms 
to levels sequester miRNAs. 
Artificial miRNA decoys, termed miRNA “sponges”, provide alternative binding platforms 
for the miRNAs and inhibit their ability to bind and suppress their endogenous targets. The 
miRNA sponges often contain a strong promoter to drive expression of binding sites for the 
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miRNA either in a non-coding transcript or in the 3’UTR of a reporter gene, like GFP. 
(Brown and Naldini, 2009, Ebert, et al., 2007) Since the interaction between miRNAs and 
target genes is largely dependent on the seed region of the miRNA, design of the miRNA 
sponges that incorporate the seed sequence can interact with all members of a miRNA seed 
family. Both individual miRNAs and large seed families, such as miR-155 and the let-7 
family, respectively, have been successfully targeted for continuous loss of miRNA function 
in multiple mammalian cell lines. (Bolisetty, et al., 2009, Kumar, et al., 2008) Compared to 
miRNA antisense oligonucleotides, a major advantage of miRNA sponges is the potential 
for stable integration for continual expression in the genome. Stable transfection of miRNA 
sponges in cultured cells led to partial derepression of miRNA target gene expression in a 
variety of cell systems, including mesenchymal stem cells (Huang, et al., 2010) and cancer 
cell models. (Bonci, et al., 2008, Valastyan, et al., 2009) A high expression level is often 
required for sufficient inhibition of endogenous miRNAs, given the much lower transgene 
copy number in stable lines compared to transient plasmid transfection. Forty integrated 
copies of a miRNA sponge targeting miR-223 driven by a weak promoter were needed to 
sufficiently suppress miR-223 expression. (Gentner, et al., 2009) Stable expression of sponges 
also enables miRNA loss-of-function studies that can span days to weeks. After 6 days, 
neurons that express anti-miR-92 sponges exhibited derepression of a potassium chloride 
cotransporter and electrophysiological changes in response to GABA treatment. (Barbato, et 
al., 2010) Both miR-144 and miR-451 were found to be required for erythropoiesis in bone 
marrow reconstitution experiments 3-4 weeks after transplantation of cells expressing 
miRNA sponges. (Papapetrou, et al., 2010)  
6. RNAi therapeutics: Development of siRNAs for disease therapy 
The potential development of new therapies for infectious disease using RNAi-based strategies 
has attracted the attention of biotechnology entrepreneurs. Multiple small companies have 
entered the field to transition RNAi from molecular biology tool to next-generation nucleotide-
based drugs for treatment of disease. In the last ten years, there have been a growing number 
of clinical trials based on siRNAs, ~20 bp short interfering RNAs that silence target genes by 
directing their cognate mRNAs for degradation by the RISC complex. (Davidson and McCray, 
2011, Vaishnaw, et al., 2010) Some programs involve local delivery of siRNAs to target tissues, 
including the eye, kidney, and liver, while others aim to achieve systemic delivery in the body. 
As with any novel strategy for drug development, there still remain technical challenges that 
need to be overcome before RNAi-based technology can successfully transition into robust 
therapies, including minimization of off-target effects (OTE) and systemic delivery of siRNAs 
in the body. A summary of these challenges and the methods that have been utilized to move 
the field of RNAi-based therapeutics forward is summarized in Table 1. Given that miRNA-
based therapies will most likely face similar challenges that are currently being addressed by 
the more mature siRNA-anchored drug companies, we provide an overview of the strategies 
utilized in siRNA-based drug discovery.  
6.1 Off-target effects  
All RNAi-based therapeutics remain vulnerable to the potential of OTE, in which expression 
of non-targeted genes is unintentionally modulated. OTE can be categorized into sequence-
dependent and sequence-independent effects. In the case of sequence-dependence, the 
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siRNAs can bind to bystander mRNAs that exhibit partial sequence complementarity but is 
unrelated to the target gene. This type of OTE can be mitigated through use of 
bioinformatics screening algorithms to design siRNA sequences that exhibit rare or no direct 
complementarity to other genome sequences aside from the target gene. In sequence-
independent OTE, the siRNAs may have inherent immunostimulatory properties or the 
endogenous miRNA pathway may be saturated, especially in the case of overexpression of 
heterologous siRNAs. For example, RNAs have been shown to stimulate the Toll-like 
receptor (TLR) (Kleinman, et al., 2008) and retinoic acid inducible gene (RIG)-I pathways. 
(Yoneyama, et al., 2004) Since there does not exist any a priori knowledge about which 
signaling pathways are activated by specific siRNAs, it may be necessary to evaluate a panel 
of pro-inflammatory markers to downselect siRNAs with comparatively reduced 
immunostimulatory properties in preclinical assays. RNAi-based therapies also need to be 
cautious about the level of exogenous siRNAs expressed in the host. In mouse studies, PolII 
promoter-driven expression of plasmid-based short hairpin RNA (shRNA) constructs in the 
liver induced host mortality, which has been attributed to saturation of the transport factor, 
Exportin 5, that ferries miRNAs from the nucleus to the cytoplasm. (Grimm, et al., 2006) 
Thus, it is necessary to determine the lowest possible concentration of siRNAs that can still 
be therapeutically effective for introduction into the host. OTEs and non-specific 
immunostimulatory responses can also be mitigated using different siRNA backbone 
modifications, including 2’-O-Me modifications (Jackson, et al., 2006) or DNA substitutions. 
(Ui-Tei, et al., 2008) Once candidate siRNAs have passed a threshold efficacy level in in vitro 
cell culture studies, leads are then assessed using good laboratory practice (GLP)-compliant 
preclinical toxicological studies with animal models such as rodents and non-human 
primates. 
6.2 siRNAs enter clinical trials  
Alnylam Pharmaceuticals currently has several advanced RNAi-based therapeutic programs 
that target multiple diseases. Alnylam has completed Phase II clinical trials on ALN-RSV01, 
a siRNA-based inhaled treatment for respiratory syncytial virus (RSV) that targets the 
nucleocapsid encoding gene in the virus. (Alvarez, et al., 2009) Lung transplant patients 
exhibited improved symptom scores and overall lung function. Alnylam has also developed 
ALN-VSP, a cocktail for two siRNAs that target vascular endothelial growth factor and 
kinesin spindle protein, as a systemically delivered liver cancer therapy. In Phase I trials, 
ALN-VSP was well tolerated and reduced tumor blood flow in patients. Finally, Alnylam 
has initiated a Phase I study of ALN-TTR01, a siRNA therapeutic that targets transthryretin 
(TTR), a carrier for thyroid hormones and retinol binding proteins, which is mutated in 
hereditary TTR-mediated amyloidosis. Pre-clinical trials have demonstrated that ALN-
TTR01 can cause regression of amyloid deposits and silence the TTR gene. 
Other companies have multiple RNAi-based drugs in the R&D pre-clinical and Phase I 
pipelines, targeting a wide range of disease conditions, including age-related macular 
degeneration (AMD) and various cancers. (Vaishnaw, et al., 2010) In addition to the 
Alnylam siRNA drug against RSV, there have been some inroads into development of 
RNAi-based therapies to treat infectious disease. For example, Tacere Therapeutics has 
developed a RNAi-based cocktail that targets three separate conserved regions of the 
Hepatitis C virus (HCV) and can be delivered to liver cells via intravenous administration 
using encapsidation in an adeno-associated protein coat. In animal studies, this therapeutic 
agent targeted and cleaved HCV at three different sites simultaneously without toxicity. In a 
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pilot Phase I/II clinical trial, Benitec Ltd., in collaboration with City of Hope National 
Medical Center, demonstrated long-term expression of three RNA-based anti-HIV moieties 
(tat/rev short hairpin RNA, TAR decoy, and CCR5 ribozyme) in hematopoietic progenitor 
cells that support the development of an RNA-based cell therapy platform for HIV. 
(DiGiusto, et al., 2010) The gene-modified stem cells had been infused into HIV-positive 
patients via autologous bone marrow transplantation to treat AIDS-related lymphomas. In 
another study, intranasal delivery of siRNAs in a SARS coronavirus (SCV) rhesus macaque 
model was also effective in reducing SARS-like physiological symptoms, RNA expression of 
SCV genes, and lung histopathology associated with viral disease. (Li, et al., 2005)  
 
Challenge    Methods to address challenge  
RNA stability   Locked nucleic acids (LNA) 
Short (7-8-mer) seed-directed anti-miRs 




Bioinformatic screening algorithms  
 
Evaluation of immunostimulatory properties 
Reduction of RNA expression levels  
Use of different RNA backbone modifications 
DNA sequence substitution 
Systemic delivery  
Chemical modifications  Cholesterol 
Chitosan  
Lipophilic molecules (e.g. bile acids) 
Packaging carriers Lipid nanoparticles (LNPs, SNALPs) 
Multiple lipid bi-layer nanoparticles (Atuplex) 
Transferrin-decorated cyclodextrin particles 
Nanoparticles decorated with leukocyte receptor antibody 
Dynamic polyconjugates 
Table 1. Transition of RNAi-based approaches to the therapeutic arena 
It is also informative to describe siRNA-based clinical trials that were terminated 
prematurely due to conclusions that the study was unlikely to yield an effective drug. 
Bevasiranib (Opko Health Inc.) and AGN211745 (Allergan Inc.) were developed to target the 
vascular endothelial growth factor (VEGF) pathways to treat patients with AMD via the 
intravitreal route. The overgrowth of blood vessels behind the retina causes irreversible loss 
of vision. Despite initial positive reports of efficacy demonstrating reduced 
neovascularization upon direct ocular injection of VEGF siRNA (Shen, et al., 2006), both 
studies were terminated during Phase II/III of clinical trials, amid suggestions that the two 
siRNAs activated TLR3 to mediate its effects in preclinical models, rather than direct 
inhibition of target gene expression. (Kleinman, et al., 2008, Vaishnaw, et al., 2010) 
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6.3 Delivery of stable siRNAs into the body 
A major technical challenge for RNAi-based therapy is drug stability in the body and 
efficient systemic delivery in sufficient quantity to have a therapeutic effect. Given their size 
and negative charge, siRNAs cannot easily cross the host cell membrane. Unmodified 
siRNAs injected into the body may be subject to RNase-mediated degradation and rapid 
renal excretion. Thus, therapeutic siRNAs are often chemically modified and/or packaged 
into carriers for delivery into the host. Various means of delivery have been tested in murine 
and non-human primate models, including in nanoparticles, complexed with 
polyconjugates, attached to cholesterol groups, or conjugated with cell surface receptors. 
(Table 1) 
Tekmira Pharmaceuticals Corp. has developed stable nucleic acid lipid nanoparticles (LNPs, 
formerly referred to as SNALPs), composed of several non-covalently associated 
components, including an ionizable lipid, polyethylene glycol (PEG)-lipid, cholesterol, and a 
neutral lipid. LNPs containing siRNAs that target several Zaire Ebola (ZEBOV) viral 
proteins were delivered into a lethal non-human primate macaque model of ZEBOV-
mediated hemorrhagic fever. (Geisbert, et al., 2010) All macaques given seven post-exposure 
treatments were protected against ZEBOV, demonstrating the efficacy of LNP-mediated 
siRNA therapy for emerging viral infections. Tekmira has also applied LNP-based delivery 
to a Phase I trial involving 23 patients with mild hypercholesterolemia. Alnylam 
Pharmaceuticals has also reported systemic delivery of siRNAs that target apolipoprotein B 
(ApoB), encapsulated in LNPs, by intravenous injection in cynomolgus monkeys. 
(Zimmermann, et al., 2006) A single injection was shown to last for more than 11 days, 
induced significant reductions in serum cholesterol and low-density lipoprotein levels, and 
resulted in greater than 90% target knockdown with no detectable toxicity. Silence 
Therapeutics has developed an independent nanoparticle approach, the AtuPlex 
technology, that embeds therapeutic siRNAs into multiple lipid bi-layer structures to 
provide systemic delivery to specific tissues. Pfizer and Quark Pharmaceuticals are 
currently testing delivery of therapeutic siRNAs using the Silence technology to treat AMD 
and diabetic macular edema in two separate Phase II trials. Pre-clinical data has indicated 
that therapy decreases onset of known endpoints in AMD.  
Calando Pharmaceuticals has initiated a Phase I clinical trial that utilizes receptor-mediated 
delivery of siRNAs encapsulated in cyclodextrin particles decorated with transferrin. Cancer 
cells, which often overexpress the transferrin receptor, are thus more likely to take up the 
particles for targeted therapeutic delivery. The trial targeted a subunit of ribonucleotide 
reductase, an enzyme required for DNA synthesis, to inhibit cancer and tumor growth. 
Tumor biopsies from melanoma patients show the presence of intracellularly localized 
nanoparticles. Furthermore, mRNA and protein levels for ribonucleotide reductase in 
tumors were decreased compared to pre-dosing tissue. (Davis, et al., 2010) Another targeted 
receptor-based strategy is siRNA delivery to a specific class of leukocytes involved in gut 
inflammation. A cyclin D1 (Cyd-1)-targeted siRNA was loaded into stabilized nanoparticles, 
the surfaces of which incorporated an antibody specific for a receptor expressed by the 
leukocytes. The targeted siRNA-containing nanoparticles down-regulated the cyclin D1 
target, suppressed leukocyte proliferation, and reversed experimentally-induced colitis in 
mice. (Peer, et al., 2008) 
Cholesterol carriers enable improved siRNA uptake in the liver, with the cholesterol easily 
bound by low-density lipoprotein (LDL) in serum and robust LDL uptake in the liver. 
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(Soutschek, et al., 2004) An siRNA targeting apolipoprotein B (apoB) has been conjugated to 
cholesterol in order to load siRNAs into circulating LDLs for enhanced stability and to 
increase receptor-mediated uptake into target hepatocytes. (Soutschek, et al., 2004, Wolfrum, 
et al., 2007) ApoB siRNAs have also been complexed with dynamic polyconjugates, PEG, 
and the liver-targeting ligand N-acetyl galactosamine to achieve site-directed delivery and 
potent ApoB knock-down. (Rozema, et al., 2007) Lipophilic siRNAs can also bind high-
density lipoprotein (HDL) and target to tissues with HDL receptors, such as gut and brain. 
(Chen, et al., 2010, Wolfrum, et al., 2007) Oral delivery of glucan-encapsulated siRNA 
particles has been reported to target Map4k4 in gut macrophages to protect mice from LPS-
induced toxicity. (Aouadi, et al., 2009) Finally, the polymer chitosan has mucoadhesive 
properties and has been used for intranasal delivery of siRNAs specific to a BCR/ABL-1 
junction sequence, into bronchiolar epithelial cells in mice, resulting in ~40% reduction of 
target gene expression. (Howard, et al., 2006)  
7. Conclusions: Strategies and future of miRNA therapeutic applications  
Recent advances in the understanding of miRNA structure and function has enabled 
development of novel miRNA-based strategies for combating human infectious disease. The 
technologies that have already been developed for stabilization and drug delivery of siRNA-
based therapeutics will no doubt accelerate transition of miRNAs into the therapeutic arena. 
Given that miRNAs are thought to regulate tens to hundreds of genes in the cell, caution 
must be taken since there may be unintended downstream consequences on cell function by 
seemingly small alterations in miRNA expression. A recent development that may greatly 
advance anti-miR therapeutics is the silencing of miRNA families with short LNA 
antagomirs that specifically target the miRNA seed sequences. (Obad, et al., 2011) The 
relatively short 7-8 nucleotide lengths of these LNA sequences may bypass the need for 
carrier formulation for systemic administration in the host and reduce the manufacturing 
costs of RNAi therapeutics. Further research, including clinical trials, will determine the 
efficacy of these short antagomirs for treatment of human disease. 
Several companies have been established to specifically develop high-impact medicines 
based on miRNAs, including Santaris Pharma A/S, Mirna Therapeutics, and Regulus 
Therapeutics. As aforementioned, Santaris has developed a LNA-based anti-miR-122 drug, 
Miravirsen, to inhibit HCV infection in Phase II clinical trials. Mirna Therapeutics has 
demonstrated intravenous administration of a neutral lipid emulsion to facilitate systemic 
delivery of tumor suppressor miRNA mimics modeled after the natural tumor suppressors 
let-7 and miR-34 to inhibit tumor growth. (Trang, et al., 2011) Regulus Therapeutics is 
focusing on both miR-21 as a potential target to reverse fibrosis and cancer onset and miR-
122 to reduce cholesterol levels and inhibit HCV infection. Other studies in the laboratory 
have implicated miRNAs in key organ function. For example, the cardiac-specific miR-208 is 
required for cardiomyocyte hypertrophy, fibrosis and expression of bMHC in response to 
stress and hypothyroidism. (van Rooij, et al., 2007) This momentum in development of 
RNAi-based drug strategies represents an exciting time for translational research that links 
fundamental bioscience discovery in cancer and infectious disease to therapeutic treatment. 
The overall promise of miRNAs as a powerful new approach to induce sequence-specific 
inhibition of gene expression has generated enormous enthusiasm and hope in the 
biomedical community that miRNA-based therapeutic treatment of disease can become a 
reality in the near future. 
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